Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

(2022) Sue Ann Costa Clemens et al.   LANCET

Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England

(2022) Nick Andrews et al.   NATURE MEDICINE

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine

(2022) Sitthichai Kanokudom et al.   Vaccines

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England

(2022) Freja C M Kirsebom et al.   LANCET INFECTIOUS DISEASES

Vaccination plus previous infection: protection during the omicron wave in Brazil

(2022) Thiago Cerqueira-Silva et al.   LANCET INFECTIOUS DISEASES

Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study

(2022) Julia Stowe et al.   Nature Communications

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

(2021) Andreas Greinacher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

(2021) Shabir A. Madhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

(2021) Amy Flaxman et al.   LANCET

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

(2021) Jamie Lopez Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

(2021) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses

(2021) Ramachandran Thiruvengadam et al.   LANCET INFECTIOUS DISEASES

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

(2021) Ronen Arbel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET